Fidaxomicin works by inhibiting RNA polymerase, an enzyme essential for bacterial RNA synthesis. This action prevents the bacteria from producing proteins vital for their survival. Because fidaxomicin is minimally absorbed from the gastrointestinal tract, it remains concentrated in the gut, which is the primary site of C. difficile infection.
